Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | ADCT-601 |
Synonyms | |
Therapy Description |
ADCT-601 is an antibody-drug conjugate comprising an antibody targeting AXL linked to PL1601, which delivers the cytotoxic agent SG3199 to AXL-expressing tumor cells, potentially leading to decreased tumor growth (Cancer Res July 1 2018 (78) (13 Supplement) 2792A). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ADCT-601 | ADCT601|ADCT 601|BGB 601|BGB601|BGB-601 | AXL Antibody 5 | ADCT-601 (BGB 601) is an antibody-drug conjugate comprising an antibody targeting AXL linked to PL1601, which delivers the cytotoxic agent SG3199 to AXL-expressing tumor cells, potentially leading to decreased tumor growth (Cancer Res July 1 2018 (78) (13 Supplement) 2792A). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
AXL over exp | renal cell carcinoma | predicted - sensitive | ADCT-601 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, treatment with ADCT-601 at the highest tested dose resulted in complete responses in 7/8 and tumor-free survival in 6/8 renal cell carcinoma cell line xenograft models expressing high levels of AXL (Cancer Res July 1 2018 (78) (13 Supplement) 2792A). | detail... |
AXL positive | triple-receptor negative breast cancer | predicted - sensitive | ADCT-601 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, ADCT-601 treatment resulted in partial responses in 5/10 and tumor-free survival in 4/10 triple-negative breast cancer cell line xenograft models expressing moderate levels of AXL (Cancer Res July 1 2018 (78) (13 Supplement) 2792A). | detail... |
AXL positive | pancreatic cancer | predicted - sensitive | ADCT-601 | Preclinical - Pdx | Actionable | In a preclinical study, treatment with ADCT-601 resulted in complete elimination of tumors in a patient-derived pancreatic cancer xenograft model expressing varied levels of AXL (Cancer Res July 1 2018 (78) (13 Supplement) 2792A). | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03700294 | Phase I | ADCT-601 | Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors | Terminated | USA | 0 |
NCT05389462 | Phase I | ADCT-601 + Gemcitabine ADCT-601 | A Dose-Escalation and Dose-Expansion Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors | Recruiting | USA | 0 |